Ethanaminium, N,N,N-trimethyl-2-[(1-oxododecyl)oxy]- | 23464-77-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Ethanaminium, N,N,N-trimethyl-2-[(1-oxododecyl)oxy]-
• 英文别名: 2-dodecanoyloxyethyl(trimethyl)azanium
• CAS: 23464-77-9
• 化学式: C17H36NO2+
• 分子量: 286.5
• InChiKey: QUDMPGCGJQLFPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  20
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Composition for External Application to Skin
  申请人：Suzuki Yasuto

  公开号：US20100273875A1

  公开（公告）日：2010-10-28

  A composition for external application to skin, containing a compound represented by formula (I) or a salt thereof, and/or a quaternary ammonium salt represented by formula (II): wherein R 1 is a substituted or unsubstituted, linear or branched chain alkyl group having 2 to 25 carbon atoms; X is —CO—NH—, —O—CO—O—, —NH—CO—, —CO—O—, —O—CO— or —O—; Y is a substituted or unsubstituted alkylene group having 1 to 4 carbon atoms; R 2 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms; R 3 is an alkyl group having 1 to 4 carbon atoms; R 2 and R 3 are the same as or different from each other; R 4 , R 5 and R 6 , which may the same as or different from each other, each are an alkyl group having 1 to 4 carbon atoms; and A − is a counter ion.

  一种用于外用于皮肤的组合物，含有由式（I）或其盐所代表的化合物和/或由式（II）所代表的季铵盐：其中，R1是具有2到25个碳原子的取代或未取代的线性或支链烷基；X是-CO-NH-，-O-CO-O-，-NH-CO-，-CO-O-，-O-CO-或-O-；Y是具有1到4个碳原子的取代或未取代的亚烷基基团；R2是氢原子或具有1到4个碳原子的烷基基团；R3是具有1到4个碳原子的烷基基团；R2和R3相同或不同；R4、R5和R6，它们可以相同也可以不同，每个都是具有1到4个碳原子的烷基基团；A-是一个反离子。
• Choline esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities
  申请人：Merck & Co., Inc.

  公开号：EP0214898A2

  公开（公告）日：1987-03-18

  Choline esters are used as drug absorption enhancing agents for drugs which are poorly absorbed from the nasal, oral, and vaginal cavities.

  胆碱酯可作为药物吸收促进剂，用于促进鼻腔、口腔和阴道吸收不良的药物。
• Pharmaceutical composition containing choline ester salts for enhancing gastrointestinal tract absorption
  申请人：Merck & Co., Inc.

  公开号：EP0206947A2

  公开（公告）日：1986-12-30

  Choline ester salts are used as drug absorption enhancing agents for orally and rectally administered drugs.

  胆碱酯盐可作为口服和直肠给药的药物吸收促进剂。
• COMPOSITION FOR EXTERNAL APPLICATION TO SKIN
  申请人：Kao Corporation

  公开号：EP2221040A1

  公开（公告）日：2010-08-25

  A composition for external application to skin, containing a compound represented by formula (I) or a salt thereof, and/or a quaternary ammonium salt represented by formula (II): wherein R1 is a substituted or unsubstituted, linear or branched chain alkyl group having 2 to 25 carbon atoms; X is -CO-NH-, -O-CO-O-, -NH-CO-, - CO-O-, -O-CO- or -O-; Y is a substituted or unsubstituted alkylene group having 1 to 4 carbon atoms; R2 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms; R3 is an alkyl group having 1 to 4 carbon atoms; R2 and R3 are the same as or different from each other; R4, R5 and R6, which may the same as or different from each other, each are an alkyl group having 1 to 4 carbon atoms; and A- is a counter ion.

  一种用于皮肤外用的组合物，含有式 (I) 所代表的化合物或其盐，和/或式 (II) 所代表的季铵盐： 其中 R1 是具有 2 至 25 个碳原子的取代或未取代的直链或支链烷基；X 是-CO-NH-、-O-CO-O-、-NH-CO-、-CO-O-、-O-CO-或-O-；Y 是具有 1 至 4 个碳原子的取代或未取代的亚烷基；R2 是氢原子或具有 1 至 4 个碳原子的烷基；R3 是具有 1 至 4 个碳原子的烷基；R2 和 R3 彼此相同或不同；R4、R5 和 R6 可能彼此相同或不同，各自是具有 1 至 4 个碳原子的烷基；以及 A- 是反离子。
• Phenylephrine pharmaceutical formulations and compositions for colonic absorption
  申请人：MSD Consumer Care, Inc.

  公开号：EP2366381A1

  公开（公告）日：2011-09-21

  The invention discloses a pharmaceutical composition comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is for oral administration wherein the composition delivers phenylephrine or a pharmaceutically acceptable salt thereof via absorption in the colon. The pharmaceutical composition comprises a core comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is in a time-dependent, pH-dependent, or colon-specific enzyme-dependent erodible layer that degrades to expose the core to release phenylephrine in the colon. In one preferred embodiment, the erodible layer encases the core. The composition optionally further comprises phenylephrine in the erodible layer or other additional layer(s). The pharmaceutical composition can further comprise one or more additional therapeutically active agents selected from one or more of the group consisting of antihistamines, analgesics, anti-pyretics, and non-steroidal anti-inflammatory agents. The invention also discloses methods of administering phenylephrine via the colon, thereby increasing the bioavailable amount of therapeutically active unconjugated phenylephrine relative to the total phenylephrine in the plasma.

  本发明公开了一种药物组合物，该组合物包含苯肾上腺素或其药学上可接受的盐和可侵蚀层，用于口服给药，其中该组合物通过结肠吸收输送苯肾上腺素或其药学上可接受的盐。该药物组合物包括由苯肾上腺素或其药学上可接受的盐组成的核心和可侵蚀层，可侵蚀层为时间依赖性、pH 依赖性或结肠特异性酶依赖性可侵蚀层，可侵蚀层降解使核心暴露，从而在结肠中释放苯肾上腺素。在一个优选的实施方案中，可侵蚀层包裹着核心。组合物还可选择在可侵蚀层或其他附加层中进一步包含苯肾上腺素。该药物组合物可进一步包含一种或多种额外的治疗活性剂，这些活性剂选自抗组胺剂、镇痛剂、解热镇痛剂和非甾体抗炎剂中的一种或多种。本发明还公开了通过结肠给药苯肾上腺素的方法，从而相对于血浆中的苯肾上腺素总量，增加了具有治疗活性的未结合苯肾上腺素的生物可利用量。